The monoethylglycinexylidide test grading of liver cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 67-75

  Fabris, L ^a   Jemmolo, R M ^a   Toffolo, G ^a   Paleari, D ^a   Viaggi, S ^b   Rigon, M ^a   Casagrande, F ^a   Lirussi, F ^a   Strazzabosco, M ^a   Cobelli, C ^a   Okolicsanyi, L ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Link Italia   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEETHYLLIDOCAINE; LIDOCAINE;

ADULT; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISCRIMINANT ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; LIDOCAINE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SENSITIVITY AND SPECIFICITY;

EID: 0032934405     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00431.x     Document Type: Article

References (42)

1. 1 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MG, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973: 60: 646-9.
2. 2 Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte eriteria in medically treated cirrhosis. Hepatology 1984; 4: 430-5.
3. 3 Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660-4.
4. 4 Henry DA, Kitchingman G, Langman MJS. Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 1985; 30: 813-18.
5. 5 Holstege A, Staiger M, Haag K, Gerok W. Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klin Wochenschr 1989; 67: 6-15.
6. 6 Birnie GG, Thompson GG, Cooke A, Brodie MJ. Antipyrine and indocyanine green kinetics in the prediction of the natural history of liver disease. Br J Clin Pharmacol 1987; 23: A615-16(Abstract).
7. 7 Marchesini G, Fabbri A, Bugianesi E, et al. Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity. Liver 1990; 10: 65-71.
8. 8 Albers I, Hartmann H, Bircher L, Creutzfeld W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24: 269-76.
9. 9 Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breath test in cirrhotic patients. Hepatology 1986; 6: 928-31.
10. 10 Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521-7.
11. 11 Oellerich M, Raude E, Burdelski M, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25: 845-53.
12. 12 Oellerich M, Ringe B, Gubernatis G, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; 1: 640-2.
13. 13 Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann HTI. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12: 219-26.
14. 14 Zoth RB, Muller T, Erhard J. et al. Quantitative liver function tests and donor specific factors in the prediction of early postoperative graft function. Lab Med 1994; 18: 439-40.
15. 15 Boyes RN, Scott DB. Jebson PJ. Godman MJ. Julian DG. Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 1971; 12: 105-16.
16. 16 Bennett PN, Aarons LJ. Bending MR, Steiner JA, Rowland M. Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. J Pharmacokin Biopharm 1982; 10: 265-81.
17. 17 Thomson AH, Elliott HL, Kelman AW, Meredith PA, Whiting B. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokin Biopharm 1987; 15: 101-15.
18. 18 Keenaghan JB, Boyes RN. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea-pigs, dogs and man. J Pharmacol Exp Ther 1972; 180: 459-63.
19. 19 Keiding S. Hepatic clearance and liver blood flow. J Hepatol 1987; 4: 393-8.
20. 20 Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 3: 913-18.
21. 21 Schaffner F, Popper H. Capillarization of hepatic sinusoids. Gastroenterology 1963; 44: 239-42.
22. 22 Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3: 275-84.
23. 23 Brodie MJ, Boobis AR, Bulpitt CJ, Davies DS. Influence of liver disease and environmental factors on hepatic mono-oxygenase activity in vitro. Eur J Clin Pharmacol 1981; 20: 39-46.
24. 24 Groszmann RJ, Atterbury CE. The pathophysiology of portal hypertension: a basis for classification. Semin Liver Dis 1982; 2: 117.
25. 25 Pieper JA, Rodman JH. Lidocaine. In. Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd edn. Spokane, Washington: Applied Therapeutics 1986: 639-81.
26. 26 Villeneuve JP, Arsene D, Huet PM. Assessment of liver function by the aminopyrine breath test. Clin Invest Med 1983; 6: 5-9.
27. 27 Zoppi F, Fumagalli C. Improved measurement of MEGX in serum with the Abbott Tdx [Letter]. Clin Chem 1992; 38: 441-2.
28. 28 Carson C, Cobelli C, Finkelstein L. The Mathematical Modeling of Metabolic and Endocrine Systems. New York: Wiley, 1983.
29. 29 SAAM II User Guide. SAAM Institute, University of Washington, 1995.
30. 30 Freiman JA, Chalmers TC, Smith H, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. New Engl J Med 1978; 299: 690-4.
31. 31 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
32. 32 Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curve derived from the same cases. Radiology 1983; 148: 839-43.
33. 33 SAS Institute. SAS user's Guide: Statistics, 5th edn. Cary NC: SAS Institute, 1985.
34. 34 Oellerich M, Burdelski M, Lautz HU, et al. Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation 1991; 51: 801-6.
35. 35 Shiffman ML, Fisher RA, Sanyal AJ, et al. Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation. Transplantation 1993; 55: 830-5.
36. 36 Arrigoni A, Gindro T, Aimo G, et al. Monoethylglycinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20: 383-7.
37. 37 Luketic VA. Shiffman ML, Fisher RA, Sanyal AJ. Purdum PP III, Posner MP. Hepatic lidocaine metabolism is useful in the selection of patients in need of liver transplantation. Transplant Proc 1993; 25: 1072-4.
38. 38 Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite - monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-7.
39. 39 Meyer-Wyss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. J Hepatol 1993; 19: 133-9.
40. 1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin Pharmacol Ther 1990; 47: 366-70.
41. 41 Bircher J. Assessment of prognosis in advanced liver disease: To score or to measure, that's the question. Hepatology 1986; 6: 1036-7.
42. 42 Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991; 14: 1029-34.